Phase 1 therapeutic clinical study of 177Lu-labelled RAD 202 for the treatment of HER2-expressing solid tumors. The open-label Phase 1 trial, entitled ‘HEAT’ (HER2 Antibody Therapy with ...

GlyTherix plans to use 177Lu-DOTA-Miltuximab in its planned Australian ... targeted radiotherapy company specializing in developing antibody radiopharmaceuticals for solid tumours.